WO2024160756 - SUPPRESSORS OF TAUOPATHIES
National phase entry is expected:
Publication Number
WO/2024/160756
Publication Date
08.08.2024
International Application No.
PCT/EP2024/052131
International Filing Date
30.01.2024
Title **
[English]
SUPPRESSORS OF TAUOPATHIES
[French]
SUPPRESSEURS DE TAUOPATHIES
Applicants **
VIB VZW
KATHOLIEKE UNIVERSITEIT LEUVEN
Inventors
VERSTREKEN, Patrik
PRASCHBERGER, Roman
Priority Data
23153997.4
30.01.2023
EP
Application details
| Total Number of Claims/PCT | * |
| Number of Independent Claims | * |
| Number of Priorities | * |
| Number of Multi-Dependent Claims | * |
| Number of Drawings | * |
| Pages for Publication | * |
| Number of Pages with Drawings | * |
| Pages of Specification | * |
| * | |
| Number of Office Actions | * |
| * | |
International Searching Authority |
EPO
* |
| Recordal of a Change of the Applicant's Name/Address |
Change of Applicant's Name and Address
* |
| Type of Assignment |
The Standard Agent's Assignment
* |
| Applicant's Legal Status |
Legal Entity
* |
| * | |
| * | |
| * | |
| * | |
| * | |
| Entry into National Phase under |
Chapter I
* |
| Patent Delivery |
Send the Letters Patent by Courier
* |
| Translation |
|
* The data is based on automatic recognition. Please verify and amend if necessary.
** IP-Coster compiles data from publicly available sources. If this data includes your personal information, you can contact us to request its removal.
Quotation for National Phase entry
| Country | Stages | Total | |
|---|---|---|---|
| China | Filing, Examination, Granting | 2185 | |
| EPO | Filing, Examination, Granting | 9404 | |
| Japan | Filing, Examination, Granting | 2055 | |
| South Korea | Filing, Examination, Granting | 1780 | |
| USA | Filing, Examination, Granting | 4740 |
Total:
20,164
The term for entry into the National Phase has expired. This quotation is for informational purposes only
Contact Us
Abstract[English]
The invention relates to field of neurodegeneration, more particularly to Tau neurotoxicity. The application identifies genes whose reduced expression suppresses pathological Tau mediated effects. These Tau suppressors are provided for use as a medicament in general, and for treating or inhibiting progression of tauopathies or symptoms of tauopathies in particular.[French]
L'invention concerne le domaine de la neurodégénérescence, plus particulièrement la neurotoxicité de Tau. L'invention identifie des gènes dont l'expression réduite supprime les effets pathologiques induits par Tau. Ces suppresseurs de Tau sont fournis pour une utilisation en tant que médicament en général, et pour le traitement ou l'inhibition de la progression de tauopathies ou de symptômes de tauopathies en particulier.